# Effects of two doses of glucose and a caffeine–glucose combination on cognitive performance and mood during multi-tasking

Andrew Scholey<sup>1</sup>\*, Karen Savage<sup>1</sup>, Barry V. O'Neill<sup>2</sup>, Lauren Owen<sup>1</sup>, Con Stough<sup>1</sup>, Caroline Priestley<sup>2</sup> and Mark Wetherell<sup>3</sup>

<sup>1</sup>Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC, Australia <sup>2</sup>GlaxoSmithKline, Middlesex, UK <sup>3</sup>Department of Psychology, Northumbria University, Newcastle-upon-Tyne, UK

**Background** This study assessed the effects of two doses of glucose and a caffeine–glucose combination on mood and performance of an ecologically valid, computerised multi-tasking platform.

**Materials and methods** Following a double-blind, placebo-controlled, randomised, parallel-groups design, 150 healthy adults (mean age 34.78 years) consumed drinks containing placebo, 25 g glucose, 60 g glucose or 60 g glucose with 40 mg caffeine. They completed a multi-tasking framework at baseline and then 30 min following drink consumption with mood assessments immediately before and after the multi-tasking framework. Blood glucose and salivary caffeine were co-monitored.

**Results** The caffeine–glucose group had significantly better total multi-tasking scores than the placebo or 60 g glucose groups and were significantly faster at mental arithmetic tasks than either glucose drink group. There were no significant treatment effects on mood. Caffeine and glucose levels confirmed compliance with overnight abstinence/fasting, respectively, and followed the predicted post-drink patterns.

**Conclusion** These data suggest that co-administration of glucose and caffeine allows greater allocation of attentional resources than placebo or glucose alone. At present, we cannot rule out the possibility that the effects are due to caffeine alone Future studies should aim at disentangling caffeine and glucose effects. © 2014 The Authors. *Human Psychopharmacology: Clinical and Experimental* published by John Wiley & Sons, Ltd.

KEY WORDS-glucose; caffeine; memory; attention; mood; multi-tasking

# INTRODUCTION

Caffeine and glucose are two of the most widely consumed centrally active substances in the world. Caffeine (and to a lesser extent glucose) are used partly because of their potential cognition-enhancing properties. Although they are often co-consumed, including increasingly in the form of energy drinks, there is surprisingly little research examining the effects of the two substances in combination in the context of neurocognitive function.

The mood and cognitive effects of caffeine have been comprehensively reviewed elsewhere (Glade, 2010; Rogers *et al.*, 2011; Smith, 2002). Typically, administration of caffeine in the range of 50 to 150 mg improves reaction times, psychomotor function, attention, vigilance and alertness-with the effects being particularly evident in fatigued individuals. Lower doses of caffeine have been less thoroughly researched, but doses as low as 12.5 mg, a level roughly equivalent to half a serving of cola, have been shown to be psychopharmacologically active (Smit and Rogers, 2000).

Glucose is the primary source of energy for the brain and, as such, is essential for central nervous system functioning. It has been extensively reported that cognitive performance can be enhanced following administration of drinks containing 25-50 g glucose. The effect is most apparent on tasks with a declarative memory component and/or those with heavier cognitive demands (Benton *et al.*, 1994; Donohoe and Benton, 1999; Riby, 2004; Scholey *et al.*, 2009b; Scholey and Fowles, 2002; Scholey *et al.*, 2001; Sünram-Lea *et al.*, 2008), including dual tasking (Foster *et al.*, 1998; Scholey *et al.*, 2009b; Smith *et al.*, 2011; Sünram-Lea *et al.*, 2002; Scholey *et al.*, 2013).

Despite the abundance of studies investigating the behavioural effects of the two substances individually, there is surprisingly little research evaluating the mood and cognitive effects of caffeine and glucose both separately and together. This has been given further

© 2014 The Authors. *Human Psychopharmacology: Clinical and Experimental* published by John Wiley & Sons, Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

<sup>\*</sup>Correspondence to: A. Scholey, Centre for Human Psychopharmacology, Swinburne University, Melbourne, VIC 3122, Australia. Tel: +61(0)3 9214 8932 E-mail: andrew@scholeylab.com

impetus from the fact that they are increasingly consumed concomitantly in so-called energy drinks.

One recent study investigating the combined and separate effects of 75 g glucose and 75 mg caffeine revealed beneficial effects to both sustained attention and learning from the combination (Adan and Serra Grabulosa, 2010). These effects were not observed in either the caffeine-only or glucose-only condition. In a follow-up study that used the same doses and included a functional magnetic resonance imaging component, the same group found no differences in performance of an attentional task between glucose, caffeine and their combination (Serra Grabulosa et al., 2010). Functional imaging during task performance, however, revealed lower activation of parietal and prefrontal cortices in the caffeine-glucose condition. These findings can be interpreted as suggesting that the caffeine-glucose drink increased 'neural efficiency', such that less brain activation was required to maintain a level of cognitive performance.

The doses used in both the aforementioned studies were 75 g glucose and 75 mg caffeine. This caffeine level is consistent with, for example, coffee, which typically contains between 50 and 100 mg caffeine. Energy drinks can also contain caffeine in the range of 75 to 200 mg caffeine or more per serving. Some, however, have lower levels more typical of colas (35–45 mg).

Regarding the amount of glucose used in the Adan and Serra Grabulosa studies, 75 g is far higher than the levels found in sweetened coffee or tea. It is also higher than the 25–50 g used in studies into glucose effects on cognition (Riby, 2004) and is relatively high compared with many caffeinated beverages such as energy drinks, which typically contain around half this amount.

Earlier studies have examined the cognitive effects of glucose and caffeine at levels more typical of everyday consumption. Compared with a glucose-andcaffeine-free control, drinks containing glucose/ caffeine at both 68 g/38 mg and 68 g/46 mg improved performance during sustained, cognitively demanding tasks (Kennedy and Scholey, 2004). Other studies indicate an additive or even synergistic effect between caffeine and glucose on various domains of cognition. In separate studies, 37.5 g glucose, 75 mg caffeine drinks improved sustained attention, working memory (Smit *et al.*, 2004), declarative memory and speed of attention (Scholey and Kennedy, 2004) above levels of either substance alone.

The distribution of attentional resources over multiple tasks engages a number of mental processes that increase cognitive demand relative to a single task performance. Moreover, the ability to effectively and accurately multi-task has great utility in planning and decision making in everyday life. Interventions that have the capacity to improve these cognitive abilities are therefore of interest both scientifically and practically. The current study was therefore designed to assess the potential effects of glucose (two doses, 25 and 60 g) and a caffeine–glucose combination (60 g glucose, 40 mg caffeine) on cognitive performance and mood associated with cognitive multi-tasking. Specifically, it aimed to investigate effects on 'everyday' cognition using a multi-tasking framework (MTF)—comprising four tasks completed simultaneously—and on mood ratings taken before and after completion of the MTF.

Two main hypotheses were tested. The primary hypothesis was that, compared with placebo, caffeineglucose in combination would result in improved cognitive multi-tasking performance as measured by overall MTF scores. We have previously argued that glucose preferentially targets more mentally effortful cognitive processes. Glucose is particularly effective at increasing performance during effortful processing, including during dual attention tasks (Scholey et al., 2009b; Sünram-Lea et al., 2002). As dividing cognitive resources over several tasks involves relatively high mental effort, we hypothesised that the two doses of glucose alone would also improve performance. The secondary hypotheses were that, compared with placebo and/or glucose alone, the caffeine-glucose combination would improve task performance on individual tasks from the MTF and improve subjective feelings of mood, stress and fatigue during extended cognitive multi-tasking.

# METHODS

# Design

The investigation was a single-centre, randomised, double-blind, placebo-controlled, parallel-groups study conducted at the Centre for Human Psychopharmacology, Swinburne University, Australia. The study was approved by the Swinburne University Human Research Ethics Committee (ref SUHREC #2010/ 299) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. The trial was registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) as ACTRN12613000247774.

The study assessed the effects of two doses of glucose alone (25 and 60 g) and one dose of a (40 mg, 60 g) caffeine–glucose combination on cognitive performance, fatigue, stress and mood associated with extended multi-tasking.

## 436

# Participants

One hundred and sixty healthy adults (male and female) aged between 18 and 55 years were recruited for the study. Participants were recruited from the investigators' existing database and via local media advertising. All participants were healthy, non-smoking, regular caffeine consumers with no significant concurrent illnesses or a history of psychiatric disease.

# Blood glucose measurement

Blood glucose levels were monitored using a MediSense Optium Xceed Blood Glucose Sensor and disposable MediSense Blood Glucose Electrodes (MediSense Britain Ltd, Birmingham, UK). The accuracy and consistency of MediSense blood glucose sensors have previously been established (Matthews *et al.*, 1987). The reliability of the test has previously been confirmed. Blood samples were taken using Owen Mumford 'Unistik 2' single-use capillary blood sampling devices (Owen Mumford Ltd, Oxford, UK). Alcohol-soaked skin cleansing swabs (Briemarkap, Koo Wee Rup, Victoria, Australia) were used for pre-sampling sterilisation.

# Salivary caffeine measurement

Saliva samples were collected using salivettes. These consist of a small test tube fitted with an inner receptacle containing a sterile cotton wool bud. Participants were required to remove the cotton wool bud and place it in the mouth, chewing gently for approximately 2 min and then replacing it in the test tube. The test tube with the saliva-cotton wool was then centrifuged, and the sample frozen for analysis. Salivary caffeine was measured using a caffeine immunoassay as previously described (Haskell *et al.*, 2005).

# Multi-tasking framework

A computerised MTF was used. This platform offers relatively high ecological validity in terms of the cognitive demands required to complete several disparate tasks simultaneously in the work environment (Wetherell and Carter, 2013). The computerised MTF comprises four cognitive and psychomotor tasks that are undertaken simultaneously using a four-way split screen.

Responses to all of the tasks are made using the mouse and cursor. Completion of the battery for an extended period has been shown to induce stress-related physiological processes (Wetherell and Sidgreaves, 2005) and to modulate subjective feelings of mood, including decreased alertness and increased mental fatigue and anxiety (Kennedy *et al.*, 2004; Scholey *et al.*, 2009a). In terms of cognitive performance, the

MTF has also been shown to be sensitive to a number of natural interventions, including food supplements and herbal extracts (Kennedy *et al.*, 2006; Kennedy *et al.*, 2004).

In this study, a 20-min version of the MTF was employed with the framework set at medium intensity (see Scholey *et al.*, 2009a, for details). The individual MTF tasks used here were as follows (arranged clockwise from top left).

*Mathematical processing task.* A series of addition calculations are presented. Each calculation requires the participant to add two numbers together, entering the three-figure answer via an onscreen number pad. On completion of each calculation, the participant clicks the 'done' button, which cues the next calculation. The outcomes are the speed of performance (number of calculations completed in 20 min) and accuracy (% correct). The module also generates an overall score incorporating correct answers (+10 points) and incorrect answers (-10 points).

Stroop colour-word task. Words describing one of four colours ('RED', 'YELLOW', 'GREEN' and 'BLUE') are presented in different coloured fonts. The participant clicks on colour panels in order to identify the font colour (e.g. if the word 'GREEN' is presented in a blue font, the correct response would be to click on the blue panel). If the participant fails to respond within 20 s, the task times out and the stimulus is replaced. The outcomes are the speed of performance (number of responses within 20 min) and accuracy (% correct). The module also generates an overall score incorporating correct answers (+10 points), incorrect answers (-10 points) and timeouts (-10 points).

*Memory search task.* Four letters appear for the participants to remember. After 4 s, the letters disappear but can be viewed again by clicking on 'retrieve list' button. Every 10 s, a single target letter appears. Participants are instructed to indicate whether the target letter had appeared in the original list of four letters by clicking on the 'yes' or 'no' buttons. If the participant fails to respond within 15 s, the task times out and the stimulus is replaced. The outcomes are the speed of performance (number of responses within 20 min) and accuracy (% correct). The module also generates an overall score incorporating the number of responses (-10 points) and timeouts (-10 points).

*Target tracker.* A red dot moves slowly outwards from the centre of target-shaped concentric circles hold

(at a speed of approximately 3 s/cm). Participants must click on one of two 'reset' buttons before the dot reaches the outer circle in order to re-centre the dot. Each larger circle increases the score by two points, from two to a maximum of 10 points. The red dot will begin to flash when touching the outer circle if reset buttons are not pressed, losing 10 points per 0.5 s until a response is made. The outcomes are the speed of performance (number of responses within 20 min) and accuracy (% correct). The module also generates an overall score incorporating number of responses and timeouts.

## Pencil-and-paper measures

Bond-Lader visual analogue mood scales. The Bond and Lader (1974) mood scales have been utilised in numerous pharmacological, psychopharmacological and medical trials. The measure comprises  $16 \times 100$  mm visual analogue mood scales with the endpoints anchored by the following antonyms: alert-drowsy, calm-excited, strong-feeble, muzzy-clearheaded, well coordinatedclumsy, lethargic-energetic, contented-discontented, troubled-tranquil, mentally slow-quick witted, tenserelaxed. attentive-dreamy, incompetent-proficient, happy-sad, antagonistic-friendly, interested-bored and withdrawn-sociable. Participants were presented with a sheet of paper containing the scales and instructed to mark their current mood state on each line. These are combined as recommended by the authors to form three mood factors, 'alert', 'calm' and 'contented', with scores on each ranging from 0 to 100.

*Stress and fatigue visual analogue mood scales.* These single visual analogue scales aim to gauge subjective mood at the present moment. The items consist of single 100-mm lines labelled 'stress' and 'fatigue' with the endpoints labelled 'not at all' and 'extremely'.

State-Trait Anxiety Inventory—State portion. The State-Trait Anxiety Inventory (STAI; Spielberger et al., 1970) comprises two scales. The 'State' (STAI-S) subscale is a widely used instrument for measuring fluctuating levels of anxiety. Participants rate how much statements match their current state by marking a 4-point scale ranging from not at all to very much so. The subscale contains 20 statements (e.g. 'I am calm'). Scores range from 20 to 80, with higher scores indicating more anxiety.

The National Aeronautics and Space Administration Task Load Index perceived workload questionnaire. The National Aeronautics and Space Administration Task Load Index (NASA-TLX; Hart and Staveland, 1988) assesses work load. Participants rate the perceived effort (from very low to very high) involved in performing the MTF along six dimensions. Three gauge the demand placed upon the respondent by the task (mental demand, physical demand and temporal demand), and three gauge elements of the interaction between participant and task (effort, frustration and perceived performance).

## Treatments

On their study day, each participant received one of four treatments supplied in the form of a 330 ml orange-flavoured drink in unlabelled bottles in opaque sleeves. The drinks comprised (i) placebo, a commercial sugar-free fizzy orange drink; (ii) 25 g glucose, in the form of a fruit-flavoured, carbonated drink (iii) 60 g glucose, in a carbonated, fruit-flavoured drink and (iv) caffeine–glucose, in the form of a commercially available, fruit-flavoured, carbonated drink containing 40 mg caffeine and 60 g glucose. Note that the glucose was in the form of glucose syrup formulated to release 60 g of glucose when broken down.

Randomisation to treatment was achieved by allocating each individual to a condition as determined by a disinterested third party who played no other part in the study.

All products contained inactive commercially available food ingredients including sweeteners (sucralose/ acesulfame K), acidulant (malic acid), preservative (potassium sorbate) and flavourings. Each participant was allowed 5 min to consume one of the treatments during their testing visit. Treatment bottles were placed in identical sleeves before consumption to maintain the double blind by preventing sighting of colour/texture differences between the treatments by researcher or participant.

Products were manufactured and supplied by GSK Nutritional Healthcare R&D (Brentford, UK) who monitored and approved chemical, sensorial and microbiological stability of the products used on study initiation and for the duration of the study. The levels of caffeine were determined by analysis, and confirmed before the start of the study.

## Procedure

Participants visited the laboratory on two occasions. The first was an initial practice session, where they signed a participant informed consent form indicating comprehension and compliance with study processes and were allocated a study identification number. Morphometric and demographic data were recorded as well as details of any relevant medical history and concomitant medications. The practice session also included measures of personality and emotional intelligence (paper questionnaires) for purposes unrelated to the current study. These included the Trait portion of the Spielberger State-Trait Anxiety scale, the Profile of Mood States, the Swinburne University Emotional Intelligence Test and the Neuroticism–Extroversion– Openness Inventory Five Factor Inventory. Participants were familiarised with the mood questionnaires including the Bond–Lader, STAI-S, visual analogue scales and NASA-TLX and practiced completing the computer-based cognitive MTF. This served to familiarise subjects with task requirements and to attenuate any practice effects.

The subsequent visit comprised the study days that took place at least 24 h after the practice visit [mean 6.51 days, standard deviation (SD) 4.52]. Participants were instructed to fast for 12h prior to study days and to abstain from drinking alcohol and caffeinated drinks for 24 and 12 h, respectively. The study day testing session lasted for 1.5 h. Upon arrival, participants provided blood and saliva for baseline fasted glucose and caffeine measurement, respectively. Following this, baseline mood, stress and fatigue measures were completed immediately before and after the computer-based MTF. The treatment drink was then administered to the participant who was allowed 5 min to consume the product. Exactly 30 min later (to allow for product absorption), a second blood glucose measure was taken. Participants again completed mood, fatigue and stress questionnaires immediately before and after completion of the MTF. After this session (60 min post-dose), final blood glucose measurement and salivary samples were provided. Participants were thanked and fully debriefed, and they were asked to indicate which condition they believed they had been in and then given the opportunity to ask questions of the experimenter before leaving the laboratory.

# STATISTICS

Sample size calculation. Sample size was determined on the basis of the data from Kennedy and Scholey (2004). Mean change-from-baseline rapid visual information processing accuracy scores were averaged across the 30-, 40- and 50-min post-treatment measures for the 40 g caffeine plus 68 g glucose and the placebo conditions, respectively. The resulting effect size (Cohen's *d*) of 0.372 was used to calculate the sample size for a four-condition analysis of variance (ANOVA) using G\*POWER v3.12 (Faul *et al.*, 2007). This generated an *N* of 132 to detect a significant difference at an  $\alpha$  level of 0.05 with 95% power. Given the exploratory nature of this study, and the possibility of attrition, the N was increased to 40/cell in order to optimise the chances of capturing treatment-related effects.

*Data treatment and analysis.* Data were analysed using the statistical software SPSS v20 for Windows unless otherwise stated.

Demographic and morphometric data were analysed using one-way ANOVA comparing treatments with pairwise comparisons where appropriate to ensure that the groups were matched. Blood glucose levels were analysed using a 2-way ANOVA examining effects of Treatment × Time (baseline, pre-testing, post-testing) with the latter as a within-subjects factor. Salivary caffeine was analysed using a 2-way ANOVA examining effects of Treatment × Time (pre-testing, post-testing) with the latter as a within-subjects factor.

The primary outcome was the overall multi-tasking score. Secondary outcomes included scores on the individual tasks. Multi-tasking performance (overall score and individual task scores) were analysed as follows. Each score was computed as change from baseline, group outliers were removed from resulting scores and data were then analysed by one-way ANOVA comparing treatments. Group differences were explored by all pairwise comparisons (least significant difference statistic).

Mood and stress reactivity (i.e. the changes in alertness, calmness, contentedness, state anxiety, stress and fatigue) were computed (post-stressor minus prestressor or  $\Delta$ ). The resulting scores were examined as change from baseline  $\Delta$  and were analysed by oneway ANOVA in the same way as the performance scores. Changes in aspects of perceived effort as measured using the NASA-TLX were analysed by one-way ANOVA examining effects of treatment (drink). Planned pairwise comparisons (least significant difference) were conducted to establish differences between active treatments and placebo and between different active drinks.

Treatment guessing data were analysed by chi-square comparing the distribution of treatment guesses to chance within each condition using GRAPHPAD software (GraphPad Software, La Jolla, CA).

# RESULTS

# Participant characteristics

Of 160 participants enrolled into the study, there were 150 suitable datasets for analysis. The flow of participants through the study is presented in Figure 1.

Participants were non-smokers and regular caffeine consumers (at least one caffeinated beverage per day). Further demographic variables are presented in



Figure 1. Flow of participants through the study, including numbers screened, entered into the study, lost to data capture errors and analysed

Table 1, and there were no group differences in any demographic or morphometric measure.

#### Blood glucose

There was a significant time × condition interaction for blood glucose levels [F(6, 292) = 20.68, p < 0.001]. Blood glucose levels did not differ at baseline [F(3, 146) = 0.91, p = 0.438]. There were significant group differences at both at the 30-min (pre-task) [F(3, 146) = 25.48, p < 0.001] and 60-min (post-task) [F(3, 146) = 27.21, p < 0.001] time points. Pairwise comparisons revealed that all measures were significantly higher than placebo at both post-baseline time points (p < 0.005) and that the 25 g drink was associated with lower blood glucose levels than the caffeine– glucose drink at the pre-task measure (p = 0.038) and both the 60 g drink and the caffeine–glucose drink at the post-test measure (p < 0.005 in both cases). These data are plotted in Figure 2 (upper panel).

# Salivary caffeine

A threshold of 2000 ng/ml salivary caffeine was used as a cut-off for compliance to overnight caffeine withdrawal (Rogers *et al.*, 2005). Compliance was high with no exclusions owing to supra-threshold salivary caffeine. There was, however, a high variability in baseline caffeine levels ranging from sub-detection levels to 1942 ng/ml.

There was a significant Treatment × Time interaction for salivary caffeine levels [F(3, 136) = 23.38, p < 0.001]. Salivary caffeine levels did not differ at baseline [F(3, 136) = 0.34, p = 0.798]. There were significant differences in the post-task samples [F(3, 136) = 7.76, p < 0.001] compared with those in the caffeine–glucose drink condition having significantly higher salivary caffeine levels than those in the placebo, 25 g glucose and 60 g glucose conditions (p < 0.005). These data are plotted in Figure 2 (lower panel).

Table 1. Demographic and morphometric characteristics of participants included in analysis

	All	Placebo	25 g glucose	60 g glucose	Caffeine-glucose
N	150	37	38	39	36
M/F	58/92	12/25	17/21	14/25	15/21
Age	34.78 (10.63)	30.51 (10.00)	31.85 (11.02)	31.44 (10.32)	34.78 (11.09)
BMI	24.36 (4.45)	24.70 (4.05)	24.10 (5.22)	23.97 (3.65)	24.72 (4.86)
Years education	17.24 (3.02)	17.00 (2.56)	17.44 (3.44)	16.95 (2.71)	17.58 (3.33)

Overall Ns and numbers of male/female (M/F) adults are shown along with mean (with standard deviation) age, body mass index (BMI), and years of education.

© 2014 The Authors. *Human Psychopharmacology: Clinical and Experimental* published by John Wiley & Sons, Ltd.

Hum. Psychopharmacol Clin Exp 2014; **29**: 434–445. DOI: 10.1002/hup



Figure 2. Mean±standard error of mean blood glucose levels (top) and salivary caffeine levels (bottom). For blood glucose **a**, significantly different to all other drink conditions; **b**, significantly different from caffeine–glucose; **c**, significantly different from 60 g glucose and caffeine–glucose at same time point. For salivary caffeine levels p < 0.005 at same time point

## Multi-tasking and mood

To ensure that the MTF had the established effects on self-rated mood, mood scores collected pre- and post-MTF were subjected to a three-way Treatment × Time (baseline, post-treatment) × MTF (pre-, post-) ANOVA. Independent of any treatment effects, the MTF had the expected effect on mood as reflected by significant main effects of MTF associated with significantly decreased calmness [F(1, 146) = 7.56, p = 0.007] and contentment [F(1, 146) = 47.83, p < 0.001], coupled with increased stress [F(1, 146) = 34.90, p < 0.001], fatigue [F(1, 146) = 79.50, p < 0.001] and state anxiety [F(1, 146) = 13.13, p < 0.001].

Prior to analysing treatment effects, each outcome measure was subject to a one-way ANOVA comparing pre-treatment baseline scores in each treatment group (presented in Table 2). There were no significant differences.

Regarding post-treatment effects, there was a significant main effect of treatment on the primary outcome variable, namely the overall multi-tasking score [F(3, 146) = 3.56, p = 0.015]. Pairwise comparisons revealed a significant difference between placebo and the caffeine–glucose drink (p = 0.005), and between the 60 g glucose and the glucose + caffeine drinks (p = 0.006)—see Figure 3. There was a significant main effect of treatment on speed of performing the mathematical reasoning task [F(3, 145) = 4.14, p = 0.008]. The glucose + caffeine group performed significantly faster than the 25 g glucose group (p = 0.034) and the 60 g glucose group (p = 0.001). There was a trend for a treatment effect for speed of responding on the Stroop task [F(3, 143) = 2.62, p = 0.054]. The caffeine–glucose drink was associated with faster responses than the placebo and the 60 g glucose drink [p = 0.027 and p = 0.011, respectively].

There were no significant treatment effects on mood measures or perceived effort as gauged using the NASA-TLX. Mean scores for the mood measures and the NASA-TLX are presented in Tables 3 and 4, respectively.

#### Treatment guessing

Overall, there was a significant bias towards guessing the glucose conditions  $[\chi^2(3) = 17.093, p = 0.0007]$  with 38.67% and 25.33% guessing that they had received 25 and 60 g glucose, respectively, compared with 18% each guessing they had received the placebo and caffeine–glucose drinks. Within each condition, however, the distribution of guesses did not differ significantly for the placebo  $[\chi^2(3)=0.407, ns], 25 \text{ g glucose}$  $[\chi^2(3)=0.897, ns], 60 \text{ g glucose } [\chi^2(3)=3.684, ns] \text{ or}$ caffeine–glucose  $[\chi^2(3)=5.444, ns]$  (Table 5).

There were no adverse events.

### DISCUSSION

Supporting our hypothesis, there was a significant treatment effect on multi-tasking performance with those in the caffeine–glucose drink outperforming the placebo condition. Multi-tasking performance was also significantly better in the caffeine–glucose condition than in the 60 g glucose drink condition. These data are consistent with the hypothesis that a caffeine–glucose drink can increase the amount of attentional resources, which can be allocated to task performance. This is in broad agreement with the results of a functional magnetic resonance imaging study showing lower levels of neural activation following a caffeine–glucose combination (albeit at different levels) than placebo or caffeine or glucose alone (Serra Grabulosa *et al.*, 2010).

Regarding the mechanisms underlying superior multi-tasking, we can be confident that the double blind was effective and that expectations as to conditions did not influence results. Treatment guessing

#### GLUCOSE, CAFFEINE AND MULTI-TASKING

#### Table 2. Summary statistics showing treatment effects (mean and SD) on multi-tasking measures

		Baseline		Post-tre	atment	Change from baseline		
		Mean	SD	Mean	SD	Mean	SD	
Multi-tasking score <sup>a</sup>	Placebo	8596	2756	9228	3006	632	1003	
c	25 g glucose	8859	2436	9848	2538	989	1195	
	60 g glucose	8754	2654	9422	2528	668	1179	
	Caffeine-glucose	9530	2277	10999	2470	1469	1538	
Mathematical reasoning score	Placebo	484	289	530	315	63	117	
	25 g glucose	369	150	377	168	8	101	
	60 g glucose	434	334	485	346	52	162	
	Caffeine-glucose	374	215	403	250	29	102	
Maths correct (number)	Placebo	53	28	57	31	6	11	
	25 g glucose	41	15	41	17	0	9	
	60 g glucose	51	27	55	28	5	16	
	Caffeine-glucose	42	20	45	23	3	10	
Maths errors (number)	Placebo	4	4	4	4	0	3	
	25 g glucose	4	4	4	2	0	4	
	60 g glucose	7	13	7	14	-1	4	
	Caffeine–glucose	5	2400	5	9	0	2	
Maths speed" (ms)	Placebo	6047	3489	5208	2627	-505	902	
	25 g glucose	5537	14/1	5266	18/1	-387	1256	
	60 g glucose	4762	1851	4558	1/11	-39	/51	
Store	Caffeine-glucose	5512	2206	4/12	1/81	-927	1270	
Stroop score	Placebo	3431	1248	3388	1439	157	027	
	25 g glucose	3730	1328	4182	1302	333	/98	
	Coffging glucose	3233	1134	3342	1107	507	815	
Stroop arror (number)	Plaasho	3301	1144	3973	1207	414	0/5	
Stroop error (number)	25 g glucose	2	2	23	3	1	3	
	60 g glucose	23	5	3	5	1	3	
	Caffeine_glucose	2	2	3	5	0	2	
Stroop speed <sup>b</sup> (ms)	Placebo	1961	1462	1869	1624	-135	238	
Subop speed (ins)	25 g glucose	1700	539	1587	566	-86	228	
	60 g glucose	1715	1054	1647	1050	-68	253	
	Caffeine-glucose	1761	770	1515	599	-218	278	
Stroop misses (number)	Placebo	27	13	27	14	0	4	
I III ( III )	25 g glucose	26	11	25	12	-1	7	
	60 g glucose	30	12	29	13	-1	6	
	Caffeine-glucose	26	12	27	12	1	5	
Tracking score	Placebo	429	59	415	80	-14	86	
-	25 g glucose	378	130	288	533	-5	74	
	60 g glucose	358	183	378	99	-11	108	
	Caffeine-glucose	384	129	362	166	-21	102	
Tracking timeouts (number)	Placebo	36	41	46	66	2	48	
	25 g glucose	71	94	151	493	1	55	
	60 g glucose	87	152	65	67	6	77	
	Caffeine-glucose	64	79	76	103	11	75	
Working memory score	Placebo	4383	1863	5002	1989	619	1157	
	25 g glucose	4728	1863	5017	1843	289	1092	
	60 g glucose	5212	2037	6260	2451	845	1344	
W7 1' ( 1 )	Caffeine-glucose	4639	2006	5232	2280	515	1142	
working memory responses (number)		504	232	559	264	43	93	
	25 g glucose	518	217	590	228	/1	121	
	Coffeine alugese	505	198	590 712	215	34	129	
Working mamory arrors (number)	Diagaba	393	221	/15	275	90	134	
working memory errors (number)	25 g glucoso	20	20	20	39	4	10	
	25 g glucose	21	24	27	20	0	13	
	Caffeine_glucose	18	16	20	29	0	12	
Working memory timeouts (number)	Placebo	38	15	36	15	-1	15	
	25 g glucose	38	12	35	16	_3	, 8	
	60 g glucose	37	12	36	14	-1	6	
	Caffeine-glucose	36	12	33	14	-3	8	
Working memory speed (ms)	Placebo	1695	1747	1600	1706	-49	207	
6 · · · · · · · · · · · · · · · · · · ·	25 g glucose	1366	661	1229	517	-100	306	
	00				- /			

(Continues)

© 2014 The Authors. *Human Psychopharmacology: Clinical and Experimental* published by John Wiley & Sons, Ltd.

*Hum. Psychopharmacol Clin Exp* 2014; **29**: 434–445. DOI: 10.1002/hup Table 2. (Continued)

		Baseline		Post-trea	atment	Change from baseline		
		Mean	SD	Mean	SD	Mean	SD	
	60 g glucose	1388	1199	1256	797	-37	197	
	Caffeine-glucose	1251	669	1109	618	-143	212	
Working memory list retrieves (number)	Placebo	3	8	3	8	0	1	
<b>č</b>	25 g glucose	2	2	1	1	0	1	
	60 g glucose	1	1	1	1	0	1	
	Caffeine-glucose	2	3	1	2	-1	1	

Means with SDs are shown.

<sup>a</sup>Significant main effect.

<sup>b</sup>Trend towards a main effect of treatment on change-from-baseline scores.





did not differ significantly by condition. We cannot, however, rule out the possibility that those in the caffeine–glucose condition were able to change their strategy to optimise their score. However, this seems unlikely as the most effective strategy to increase overall score is to focus on the working memory task, and there was no evidence that this was the case. There were significant improvements to the speed of performing mental arithmetic associated with the caffeine–glucose drink. Those in the combination drink were faster than either glucose drink alone, again suggesting that caffeine conferred a benefit to performance. Mathematical processing requires manipulation of information held in consciousness and, like multi-tasking, draws heavily on working memory and

Table 3. Summary statistics showing treatment effects (mean and SD) on mood measures

		Base pre-l	eline MTF	Base post-	eline MTF	Base char	line 1ge	Treat pre-]	iment MTF	Trea post-	tment MTF	Treati char	nent Ige	Cha pre-l	nge MTF	chan	ge $\Delta$
		Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Alert	Placebo	57	20	59	17	2	15	66	15	65	18	-1	16	8	19	-2	20
	25 g glucose	60	17	61	18	1	11	67	14	66	17	-1	10	7	13	-2	1
	60 g glucose	56	20	53	19	-3	18	60	17	59	20	-1	16	4	17	2	20
	Caffeine-glucose	63	18	60	19	-3	16	71	14	66	16	-5	15	9	14	-2	18
Calm	Placebo	67	16	58	20	-9	18	58	65	54	19	-4	16	-9	20	6	22
	25 g glucose	69	13	58	18	-10	17	65	17	55	22	-10	15	-4	13	1	13
	60 g glucose	64	17	57	16	-8	16	60	16	55	16	-5	13	-4	18	3	17
	Caffeine-glucose	70	15	59	18	-12	13	61	20	59	21	-2	20	-9	16	10	17
Content	Placebo	70	16	68	16	-2	12	72	14	73	14	1	11	2	13	4	15
	25 g glucose	70	15	69	15	-1	10	73	13	72	15	-2	8	3	9	-1	10
	60 g glucose	67	12	62	12	-5	13	69	11	66	13	-3	10	2	12	2	11
	Caffeine-glucose	71	20	67	16	-4	15	72	13	71	12	-2	9	-1	10	3	19
Fatigue	Placebo	46	2.65	54	2.06	0.72	2.22	37	2.10	49	2.38	1.21	2.34	-0.92	2.34	0.59	2.92
-	25 g glucose	41	2.29	52	2.09	1.14	1.98	36	1.85	50	2.28	1.42	1.99	-0.47	1.48	0.33	2.18
	60 g glucose	40	2.75	51	2.56	1.09	2.16	35	2.33	49	2.42	1.45	2.39	-0.57	2.88	0.42	3.13
	Caffeine-glucose	39	2.69	53	2.47	1.39	2.23	29	1.83	44	2.48	1.55	2.51	-0.96	2.46	-0.18	1.97
Stress	Placebo	28	2.17	39	2.38	1.23	2.28	28	1.77	40	2.57	1.24	2.21	0.16	1.58	0.07	2.06
	25 g glucose	26	1.98	39	1.99	1.31	2.02	29	1.94	41	2.24	1.22	2.02	0.24	1.94	-0.04	1.79
	60 g glucose	23	1.98	38	2.12	1.50	1.71	25	1.89	35	2.27	0.97	1.99	0.23	1.91	-0.45	2.39
	Caffeine-glucose	26	2.35	42	2.41	1.64	2.48	26	2.21	37	2.58	1.18	2.26	0.19	1.22	-0.84	2.39
State anxiety	Placebo	45	5.05	44	5.17	-0.92	3.57	44	4.84	43	6.02	-0.05	4.8	-0.89	3.67	0.42	5.33
	25 g glucose	45	5.60	43	5.06	-1.49	4.01	43	5.25	44	5.3	0.4	3.09	-1.65	3.67	1.89	5.13
	60 g glucose	44	4.88	44	4.20	-0.27	4.07	43	5.24	43	5.89	0	4.82	-0.78	4.41	0.27	6.18
	Caffeine-glucose	44	4.62	42	4.69	-2.84	3.85	44	5.46	42	6.41	-1.67	3.81	-1	2.85	1.16	4.15

© 2014 The Authors. *Human Psychopharmacology: Clinical and Experimental* published by John Wiley & Sons, Ltd.

Hum. Psychopharmacol Clin Exp 2014; 29: 434–445. DOI: 10.1002/hup

#### GLUCOSE, CAFFEINE AND MULTI-TASKING

		Baseline		Post-trea	atment	Change from baseline		
		Mean	SD	Mean	SD	Mean	SD	
Mental demand	Placebo	61	21	60	24	-1	16	
	25 g glucose	63	18	58	24	-4	19	
	60 g glucose	53	23	53	25	-1	21	
	Caffeine-glucose	59	17	58	18	0	15	
Physical demand	Placebo	28	21	32	26	4	16	
•	25 g glucose	29	22	27	20	-2	13	
	60 g glucose	29	25	33	26	5	12	
	Caffeine-glucose	24	18	31	22	8	18	
Temporal demand	Placebo	65	20	62	25	-3	22	
1	25 g glucose	63	19	61	24	-2	18	
	60 g glucose	60	17	55	22	-5	19	
	Caffeine-glucose	60	18	55	21	-5	15	
Performance	Placebo	34	17	32	16	-3	19	
	25 g glucose	41	17	37	21	-4	20	
	60 g glucose	44	22	40	22	-4	20	
	Caffeine-glucose	35	20	33	22	-2	23	
Effort	Placebo	68	18	65	19	-2	11	
	25 g glucose	66	17	63	24	-3	14	
	60 g glucose	64	21	62	20	-2	18	
	Caffeine-glucose	62	18	56	21	-7	17	
Frustration	Placebo	42	24	42	22	0	22	
	25 g glucose	36	23	36	24	0	16	
	60 g glucose	42	22	40	23	-2	22	
	Caffeine-glucose	36	26	37	23	1	20	

Table 4. Summary statistics showing treatment effects (mean and SD) on measures derived from the NASA-TLX

Table 5. Number of participants guessing which treatment they had received by condition

	Treatment guessed (N)									
	Placebo	25 g glucose	60 g glucose	Caffeine-glucose						
Placebo	6	15	8	8						
25 g glucose	6	17	10	5						
60 g glucose	8	14	14	3						
Caffeine-glucose	7	12	6	11						
p	0.938	0.826	0.298	0.142						

p indicates probability of difference from chance values within each treatment guessed.

executive processes. Taken together, these findings suggest that the caffeine–glucose combination can improve executive functioning through the allocation of more attentional resources to multi-task performance. There was also some evidence of improvements to the speed of responding on the Stroop module. The Stroop task is a classic measure of selective attention and response inhibition. Again, effective performance relies on executive responses—in this case, inhibiting the response to the word meaning in favour of its perceptual properties.

Counter to our hypotheses, there were no behavioural effects of either dose of glucose alone. Those in the 25 g glucose condition had numerically better performance (although this did not approach statistical

significance), whereas performance in the 60 g condition was similar to that in placebo and significantly worse than that in the caffeine-glucose drink. These performance differences between the two glucose-only conditions support the notion of an inverted U doseresponse curve for glucose on some aspects of cognition (Riby, 2004). With regard to specific outcomes, in previous studies examining the effects of glucose on sequentially performed tasks, 25 g glucose has improved working memory (serial subtraction) performance (Scholey et al., 2001). On the other hand, performance of a task very similar to the working memory module in the current study was unaffected by 37.5 g glucose, either alone or in combination with glucose (Scholey and Kennedy, 2004). Owen et al. (2012) specifically compared the mood and cognitive effects of 25 and 60 g glucose drinks. Her data reveal a complex pattern of effects, with the two doses interacting differentially with task type and fast duration. The 25 g drink was associated with better serial sevens performance following a 2-h fast only, and faster choice reaction times following an overnight fast only. The 60 g dose speeded word recognition and improved serial threes performance following an overnight (but not 2 h) fast. None of the affected tasks were a direct analogue of those in the current study. Nevertheless, we have previously argued that tasks that require higher levels of mental effort for effective

execution are more susceptible to the glucose enhancement effect. It might be assumed that multi-tasking would fall into this category, and indeed the mood changes associated performing the MTF support this contention. On the other hand, previous studies that have found effects of glucose (usually 25 g) during dual tasking have included more individual task such as effortful psychomotor tracking (Scholey et al., 2009b) or repeated, alternating hand movements (Sünram-Lea et al., 2002). The effect may be because such tasks are more effortful than the MTF used in the current study, for example, co-performing hand movements can reduce memory performance to near chance levels (Scholey et al., 2013; Scholey et al., 2006). Alternatively, previous dual tasking studies have typically included a declarative memory component, which may be more susceptible to the glucoserelated enhancement.

These positive effects seen here may be due to the additive/synergistic effects of glucose and caffeine in combination, supporting previous behavioural studies showing that the effects of caffeine and glucose together were significantly better than those of either substance alone (Scholey and Kennedy, 2004). Alternatively, at present, we cannot rule out the possibility that they may be attributable to caffeine contained within this treatment only. Future studies should compare the effects of caffeine alone with the other treatments used in the current study.

There were no mood changes associated with any drink. This is consistent with much of the previous literature regarding glucose. However, caffeine is often associated with alerting effects, although these are most easily detected in individuals who are in a deprivation state owing to (e.g.) fatigue and are most readily found with higher caffeine doses. In any case, these findings suggest that the significant improvement in multi-tasking performance following the caffeine– glucose drink reflects direct effects on performance rather than a secondary effect of improved arousal/ alertness.

It is worth noting that the mean body mass index of the participants is towards the high end of the normal range (mean body mass index = 24.36, *SD* 4.47). We have previously reported that body composition differentially influences glucose absorption and possibly cognitive responses to glucose (Owen *et al.*, 2013). Further work might usefully be directed to discerning the effect of body composition on cognitive responses to various nutritional interventions.

In summary, a drink containing 40 mg caffeine/60 g glucose improved performance of an ecologically valid task of multi-tasking. As the same drink improved

aspects of executive functioning and attention, it is possible that increased allocation of attentional resources underlie this effect. Further work should be aimed at delineating the underlying mechanisms of these effects, including the use of functional brain imaging. It would be of great interest to examine different levels of glucose in combination with caffeine in order to determine the threshold levels of the two substances for positive effects on multi-tasking.

## CONFLICT OF INTEREST

B. V. O. N. and C. P. are employees of GlaxoSmithKline. A. S., L. O. and C. S. have received research funding, consultancy and/or speakers fees from industry sources. The other authors declare no conflict of interest.

#### ACKNOWLEDGEMENT

This study was funded by GlaxoSmithKline and grant number DP1093834 from the Australian Research Council.

#### REFERENCES

- Adan A, Serra Grabulosa JM. 2010. Effects of caffeine and glucose, alone and combined, on cognitive performance. *Hum Psychopharmacol* 25: 310–317.
- Benton D, Owens DS, Parker PY. 1994. Blood glucose influences memory and attention in young adults. *Neuropsychologia* **32**: 595–607.
- Bond A, Lader M. 1974. The use of analogue scales in rating subjective feelings. *Br J Med Psychol* **47**: 211–218.
- Donohoe RT, Benton D. 1999. Declining blood glucose levels after a cognitively demanding task predict subsequent memory. *Nutr Neurosci* **2**: 413–424.
- Faul F, Erdfelder E, Lang A-G, Buchner A. 2007. G\*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 39: 175–191.
- Foster J, Lidder P, Sünram S. 1998. Glucose and memory: fractionation of enhancement effects? *Psychopharmacology (Berl)* **137**: 259–270.
- Glade MJ. 2010. Caffeine-not just a stimulant. Nutrition 26: 932-938.
- Hart SG, Staveland LE. 1988. Development of NASA-TLX (Task Load Index): results of empirical and theoretical research. *Hum Mental Workload* 1: 139–183.
- Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. 2005. Cognitive and mood improvements of caffeine in habitual consumers and habitual nonconsumers of caffeine. *Psychopharmacol* 179: 813–825.
- Kennedy DO, Scholey AB. 2004. A glucose–caffeine 'energy drink' ameliorates subjective and performance deficits during prolonged cognitive demand. *Appetite* 42: 331–333.
- Kennedy DO, Little W, Scholey AB. 2004. Attenuation of laboratoryinduced stress in humans after acute administration of *Melissa officinalis* (lemon balm). *Psychosom Med* 66: 607–613.
- Kennedy DO, Little W, Haskell LF, Scholey AB. 2006. Anxiolytic effects of a combination of *Melissa ofcinalis* and *Valeriana ofcinalis* during laboratory induced stress. *Phytother Res* 20: 96–102.
- Matthews D, Holman R, Bown E, et al. 1987. Pen-sized digital 30-second blood glucose meter. Lancet 1: 778.
- Owen L, Scholey AB, Finnegan Y, Hu H, Sünram-Lea SI. 2012. The effect of glucose dose and fasting interval on cognitive function: a doubleblind, placebo-controlled, six-way crossover study. *Psychopharmacol* 220: 577–589.
- Owen L, Scholey A, Finnegan Y, Sünram-Lea SI. 2013. Response variability to glucose facilitation of cognitive enhancement. *Br J Nutr* **110**: 1873–1884.

- Riby LM. 2004. The impact of age and task domain on cognitive performance: a meta-analytic review of the glucose facilitation effect. *Brain Impairment* 5: 145–165.
- Rogers PJ, Heatherley SV, Hayward RC, Seers HE, Hill J, Kane M. 2005. Effects of caffeine and caffeine withdrawal on mood and cognitive performance degraded by sleep restriction. *Psychopharmacol* 179: 742–752.
- Rogers P, Smith J, Benton D. 2011. Caffeine, mood and cognition. In *Lifetime nutritional influences on cognition, behaviour and psychiatric illness* Benton D (ed). Woodhead Publishing: Cambridge; 251–271.
- Scholey AB, Fowles KA. 2002. Retrograde enhancement of kinesthetic memory by alcohol and by glucose. *Neurobiol Learn Mem* 78: 477–483.
- Scholey AB, Kennedy DO. 2004. Cognitive and physiological effects of an "energy drink": an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. *Psychopharmacol* **176**: 320–330.
- Scholey AB, Harper S, Kennedy DO. 2001. Cognitive demand and blood glucose. *Physiol Behav* 73: 585–592.
- Scholey AB, Laing S, Kennedy DO. 2006. Blood glucose changes and memory: effects of manipulating emotionality and mental effort. *Biol Psychol* 71: 12–19.
- Scholey A, Haskell C, Robertson B, Kennedy D, Milne A, Wetherell M. 2009a. Chewing gum alleviates negative mood and reduces cortisol during acute laboratory psychological stress. *Physiol Behav* 97: 304–312.
- Scholey A, Sünram-Lea S, Greer J, Elliott J, Kennedy D. 2009b. Glucose administration prior to a divided attention task improves tracking performance but not word recognition: evidence against differential memory enhancement? *Psychopharmacol* 202: 549–558.
- Scholey A, Macpherson H, Sünram-Lea S, Elliott J, Stough C, Kennedy D. 2013. Glucose enhancement of recognition memory: differential effects on effortful processing but not aspects of 'remember-know' responses. *Neuropharmacology* 64: 544–549.

- Serra Grabulosa JM, Adan A, Falcón C, Bargalló N. 2010. Glucose and caffeine effects on sustained attention: an exploratory fMRI study. *Human Psychopharmacol* 25: 543–552.
- Smit H, Rogers P. 2000. Effects of low doses of caffeine on cognitive performance, mood and thirst in low and higher caffeine consumers. *Psychopharmacol* 152: 167–173.
- Smit H, Cotton J, Hughes S, Rogers P. 2004. Mood and cognitive performance effects of "energy" drink constituents: caffeine, glucose and carbonation. *Nutritional Neurosci* 7: 127–139.
- Smith A. 2002. Effects of caffeine on human behavior. *Food Chem Toxicol* **40**: 1243–1255.
- Smith MA, Riby LM, Eekelen JAM, Foster JK. 2011. Glucose enhancement of human memory: a comprehensive research review of the glucose memory facilitation effect. *Neuroscience & Biobehavioral Reviews* 35: 770–783.
- Spielberger CD, Gorsuch RL, Lushene RE. 1970. Manual for the State-Trait Anxiety Inventory.
- Sünram-Lea SI, Foster JK, Durlach P, Perez C. 2002. Investigation into the significance of task difficulty and divided allocation of resources on the glucose memory facilitation effect. *Psychopharmacol* 160: 387–397.
- Sünram-Lea S, Dewhurst S, Foster J. 2008. The effect of glucose administration on the recollection and familiarity components of recognition memory. *Biol Psychol* 77: 69–75.
- Wetherell MA, Carter K. 2013. The multitasking framework: the effects of increasing workload on acute psychobiological stress reactivity. *Stress Health* 30: 103–109.
- Wetherell MA, Sidgreaves MC. 2005. Secretory immunoglobulin A reactivity following increases in workload intensity using the Defined Intensity Stressor Simulation (DISS). *Stress and Health* **21**: 99–106.